FDA Peptide Update: Category 2 Removals Explained FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of : ? The FDA just removed 12 peptides (BPC157, TB500, Epitalon, GHKCu inj., DSIP, MOTSc, Semax, PEGMGF, Melanotan II, LL37, Dihexa, KPV) from Category 2 (donotcompound The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them